



PRECISION HEART AI



Transforming *Hidden ECG Signals* into
Actionable Cardiovascular Intelligence



Early Detection. Earlier Intervention.
Better Outcomes.




Precision Heart AI represents a *high-conviction investment opportunity* at the intersection of *artificial intelligence* and *cardiovascular care*



Precision Heart AI, 8585 Miramar Place,
San Diego, California, 92121, United States (US)



ECN-DM: TRANSFORMING HEART HEALTH MEDICINE



- After decades of research & development, our **ECN-DM (Electro Cardio Nanogram - Dispersive Mapping)** technology can detect even minor electrophysiological and metabolic changes in the heart cells before disease develops and progresses.



- Traditional golden standard heart disease diagnostic methods are **not effective** in detecting heart health shifts prior to pathological changes, especially in **asymptomatic patients**.



- ECN-DM complements traditional heart diagnostic tests offering **a more comprehensive, preventive approach** to heart health.



- With a **92% positive predictive value (PPV)**, our technology not only diagnoses existing conditions but also **predicts** them preemptively, outperforming all noninvasive gold-standard heart tests and revolutionizing preventive healthcare.



THE PROBLEM



- Cardiovascular disease remains the **leading cause of death worldwide**.



- Despite the widespread use of ECG testing, **many cardiovascular conditions remain undetected** until advanced disease or acute events occur because ECG analysis focusses on a **limited set of visible waveform characteristics**.



- **Subtle electrical signatures** embedded within the cardiac cycle are routinely filtered or **classified as noise**, despite their potential diagnostic significance.



- Clinicians lack **affordable, scalable tools** capable of **identifying ischemic risk before conventional diagnostic indicators emerge**, resulting in **delayed intervention, increased healthcare costs, and preventable morbidity and mortality**.



OUR INSIGHT



- The ECG contains **significantly more information** than current diagnostic methodologies utilize.



- Precision Heart AI's core hypothesis: **Micro-electrical variations** embedded within the **PQRST cycle** contain clinically relevant biomarkers associated with ischemia and other cardiovascular abnormalities.



- Conventional ECG systems **suppress or ignore** these signals.



- We designed a system to **extract, amplify, and interpret** them.



THE SOLUTION

ECN-DM™

Electro-Cardio Nanogram-Dispersive Mapping

Our platform combines:



- Proprietary Amplifier
signal enhancement technology



- Advanced AI-based
pattern recognition



- Standard ECG
signal acquisition



- Automated risk assessment
workflows



The system **transforms** previously discarded ECG signal information into **clinically actionable diagnostic insights**.



THE ECN-DM™ SYSTEM

Advanced Technology. Actionable Results.

A breakthrough diagnostic platform that transforms how cardiovascular risk is detected and managed.

1 THE ECN-DM™ SYSTEM



The ECN-DM is a **six-lead system** derived through 4 contacts, one on each wrist and one on each ankle.

 Average test time
3 MINUTES



 Results return in
30 SECONDS

2 ADVANCED 3D HEART RENDERING


A negative hypoxia and/or ischemia screen result will show the heart as green/blue.

A positive hypoxia and/or ischemia screen result will show the heart as red

15:11, 2016 10:22



Myocardium 14%
Rhythm 24%
Pulse 55



The results display a 3D rendering of the heart which has been divided into **512 sections** per the DM (Dispersive Mapping) isolating the exact location of the issue.



NON-INVASIVE

Safe, fast and patient-friendly



QUICK RESULTS

3-minute test with 30-second results



PRECISION MAPPING

512-section analysis for unmatched accuracy



ACTIONABLE INSIGHTS

Identify risk and guide clinical decision-making

PRECISION. SPEED. CLARITY. TRANSFORMING CARDIOVASCULAR CARE.



TECHNOLOGY

HOW IT WORKS

1



- Standard ECG data is acquired.

2



- Amplifier technology isolates and **enhances** micro-electrical variations.

3



- **AI models** evaluate hidden signal characteristics.

4



- Diagnostic algorithms **identify patterns** associated with cardiovascular dysfunction.

5



- Clinicians receive **actionable risk indicators**.

KEY ADVANTAGE:



No new
invasive
procedure.



No expensive
imaging.



No radiation
exposure.



Simply more
information
extracted from
an existing test.

MARKET OPPORTUNITY

CHANNEL	ESTIMATED U.S. COUNT (2026)	WHY IT MATTERS TO PRECISION HEART AI
 Cardiology practices	~2,500 practices	Specialty adoption channel for high-risk cardiovascular patients
 Primary care practices/networks	~30,000–35,000 organizations	Largest screening opportunity for early detection
 Hospitals	~6,100 hospitals	Acute care, outpatient screening, ED triage
 Integrated delivery systems (IDNs)	900+ systems	Enterprise-scale buyers capable of deploying across multiple sites
 Employer health programs (self-insured)	~49,400 self-insured employer plans	Preventive screening market focused on reducing downstream costs
 Federal, state, and local government screening initiatives	50 state programs + hundreds of local initiatives + major federal systems	Public health and veteran screening opportunities



Precision Heart AI's ECN-DM platform addresses multiple healthcare channels capable of supporting large-scale preventive cardiovascular screening—spanning **more than 80,000 potential organizational customers** in the United States alone.



COMPETITIVE LANDSCAPE



ECG

- Low cost
- Limited sensitivity for early disease

\$20 – \$100
per test



STRESS TESTING

- Higher cost
- Time intensive

\$300 – \$1,000
per test



CT ANGIOGRAPHY

- Expensive
- Radiation exposure

\$1,000 – \$2,500
per test



ADVANCED IMAGING

- Limited scalability

\$1,500 – \$5,000+
per test



PRECISION HEART AI

- ✓ Non-invasive
- ✓ Low-cost workflow
- ✓ AI-enhanced interpretation
- ✓ Compatible with existing ECG infrastructure
- ✓ Designed for early detection

\$50 – \$150
per test

Note: Price ranges are approximate and vary by provider, geography, and setting. Sources: Medicare Fee Schedule, Fair Health Consumer Database, industry reports, and public pricing information (2023–2024).



REGULATORY STRATEGY



REGULATORY PATHWAY

- FDA strategy underway
- Predicate and *De Novo* pathway evaluation completed
- Clinical validation roadmap established
- Quality and documentation processes being prepared for regulatory submission



OBJECTIVE:

Achieve FDA 510(k) clearance while building a defensible clinical evidence base.



INTELLECTUAL *PROPERTY*



DEFENSIBLE TECHNOLOGY PLATFORM

- *Proprietary Amplifier methodology*
- *Signal processing architecture*
- *AI classification models*
- *Diagnostic workflow innovations*
- *Trade secrets and future patent filings*



*The moat is not simply AI.
The moat is the **unique signal acquisition**
and **interpretation framework**.*





BUSINESS MODEL

Multiple revenue streams. One **scalable** platform. Significant **long-term value**.



FUTURE DATA NETWORK OPPORTUNITIES

- De-identified ECG data network to enhance AI performance
- Real-world evidence generation and outcomes research
- Potential for data insights partnerships and licensing



POPULATION SCREENING PROGRAMS

- Risk stratification at scale in employers, payors, and community settings
- Enables early detection and preventive care initiatives



DIAGNOSTIC PARTNERSHIPS

- Collaborations with cardiology groups, imaging centers, and telecardiology providers
- Shared value models to expand patient access and drive referrals



ENTERPRISE HEALTH SYSTEM CONTRACTS

- System-wide licensing across hospitals and outpatient sites
- Volume-based pricing with tiered structures
- Integration, training, and performance analytics included



PER-TEST REIMBURSEMENT

- CPT Category III code strategy in development
- Designed to align with existing reimbursement pathways
- Drives adoption through clinical utility and measurable impact



SOFTWARE LICENSING

- Annual or multi-year licenses for our AI-powered ECN-DM™ platform
- Deployed on-premise or in the cloud
- Includes updates, support, and continuous AI improvements



**SCALABLE RECURRING REVENUE MODEL
WITH STRONG OPERATING LEVERAGE**



High gross margins



Increased value with usage and scale



Durable relationships and long-term contracts



COMMERCIALIZATION STRATEGY & FINANCIAL OUTLOOK

Conservative Revenue Model

Built upon existing customer relationships, staged FDA milestones, and measured commercial expansion.

REVENUE DRIVERS



East Coast Cardiology Group

- Initial deployment
- Pre-FDA revenue generation
- Volume expansion after clearance



Midwest Healthcare Client

- Reimbursement-driven growth
- Higher value diagnostic testing



East Coast Physician Network

- 5,000 physician network
- Scalable subscription model



Equipment Sales

- Initial deployment
- Additional expansion purchases

KEY YEAR 1 METRICS



\$12.1M

Projected Year One Revenue



\$8.06M

Projected EBITDA
(Earnings Before Taxes)



199%

Projected Annual Margin



3

Major Commercial Customers



FDA CLEARANCE

Catalyst for accelerated growth

COMMERCIAL INFLECTION TIMELINE



MONTHS 1-3

Platform deployment



MONTHS 4-8

Initial revenue generation



MONTHS 9-10

Commercial acceleration



MONTHS 11-12

Large network expansion



Foundation Phase

Technology deployment
and initial adoption



Growth Phase

Expanding utilization
and revenue base



Scale Phase

Network expansion
drives significant growth



Value Realization

High margins and
strong cash generation



Conservative assumptions produce a path toward profitability during Year One of commercialization.



USE OF CAPITAL & FINANCIAL ROADMAP

Strategically investing to achieve FDA clearance, scale manufacturing, and accelerate commercial adoption.

\$2 MILLION CAPITAL RAISE

Funds allocated toward:



FDA 510(k) Clearance
Regulatory submission and clearance pathway



Manufacturing Scale-Up
Equipment, production capacity and quality systems



Commercial Marketing
Market awareness, customer acquisition and demand generation



Working Capital
Operational runway and business execution



Strategic Growth
Expand partnerships and commercial footprint

ITEMIZED USE OF CAPITAL

Use of \$2M Capital Raise

	FDA 510(k) Clearance	\$250,000
	Hardware Purchase 850 Electrode Units	\$650,000
	Initiate Patent Process	\$45,000
	Programming / Server Setup	\$125,000
	Professmng Fees – Accounting & Legal	\$38,000
	Salaries and Consultants	\$385,000
	Promotion & Marketing	\$277,000
	Rent	\$36,000
	Internet	\$44,000
	Travel / Conventions / Entertainment	\$50,000
	Commission on Raise	\$100,000

TOTAL CAPITAL RAISE
\$2.0M

PROJECTED YEAR ONE RESULTS

Conservative Model



REVENUE **\$12.1M**



TOTAL EXPENSES **\$4.04M**



EARNINGS BEFORE
TAXES (EBT) **\$8.06M**



PROJECTED
ANNUAL MARGIN **199%**



Strong revenue ramp and operating leverage
drive profitability during Year One.

INVESTMENT THESIS



Existing customer relationships
Established demand and early revenue visibility



Scalable SaaS + diagnostic model
High-margin recurring revenue with expansion potential



FDA milestone creates revenue acceleration
Cleared pathway unlocks larger markets



Attractive operating leverage
Strong margin profile drives significant cash flow



Large expansion opportunity
Underserved market with substantial growth runway



Precision Heart AI is positioned to **transform** early cardiovascular diagnostics through a scalable, high-margin business model.



SCALING THE PLATFORM & YEAR 2 OUTLOOK

Commercial Momentum Driving Accelerated Growth

Following FDA clearance and initial market validation, Precision Heart AI is positioned for significant expansion across multiple healthcare channels.

REVENUE EXPANSION



East Coast Cardiology Group
Growing utilization following FDA clearance.



Midwest Healthcare Client
Expanding reimbursement-supported testing.



East Coast Physician Network
5,000 physician network driving recurring diagnostics.



Additional Healthcare Clients
Strategic customer diversification.



Equipment Sales
Growing installed base fuels recurring revenue.

\$75M+

PROJECTED REVENUE

\$62M

PROJECTED EBT
(EARNINGS BEFORE TAXES)



\$75M

Projected Revenue



\$62M

Projected EBT



510%

Projected Annual Margin



5

Major Commercial Revenue Channels



FDA CLEARED
Commercial scaling platform

COMMERCIAL GROWTH PATH



PHASE 1

Expand existing customer relationships.



PHASE 2

Increase physician network penetration.



PHASE 3

Add strategic healthcare partners.



PHASE 4

Scale installed equipment base.



PHASE 5

Build recurring diagnostic revenue.

PROJECTED YEAR 2 RESULTS



REVENUE

\$75M



EARNINGS BEFORE TAXES

\$62M



ANNUAL MARGIN

510%

KEY YEAR 2 DRIVERS



Growing installed device base



Recurring diagnostic revenue



Expanded physician adoption



Additional healthcare partnerships



Attractive operating leverage

INVESTMENT MESSAGE



Year 2 reflects the **transition from product commercialization to platform expansion**, leveraging FDA clearance, recurring diagnostic revenue, and scalable healthcare partnerships to accelerate growth.

SCALABLE PLATFORM. RECURRING REVENUE. SUSTAINABLE GROWTH.

WHY NOW

Three major shifts are converging:

1



AI has matured sufficiently for complex biosignal analysis.

92%

accuracy in detecting cardiac events with AI-powered ECG algorithms (vs. 78% traditional methods).

Source: Nature Medicine, 2023

2



Healthcare is moving toward prevention and early intervention.

70%

of cardiovascular disease is preventable with early detection and risk management.

Source: American Heart Association, 2023

3



Cardiovascular costs continue to rise globally.

\$1.1T

projected global cost of cardiovascular disease by 2030.

Source: World Heart Federation, 2023



The industry is actively searching for **earlier, lower-cost diagnostic solutions.**

THE GROWING BURDEN OF CARDIOVASCULAR DISEASE



523M

people worldwide live with cardiovascular disease.

Source: World Health Organization, 2023



\$863B

annual cost to the U.S. healthcare system.

Source: American College of Cardiology, 2023



5.7%

CAGR of the global cardiovascular diagnostics market through 2030.

Source: Market.us, 2023



THE TEAM

*A multidisciplinary team of proven leaders, scientists,
and experts building the future of cardiovascular diagnostics.*

LEADERSHIP

Vladimir Podlipiski, Ph.D.

Founder & CEO

Senior science and business executive with extensive experience in life sciences, bioorganic chemistry, and advanced product development.

- Development of novel cardiovascular screening and diagnostic devices
- Advanced biosignal analysis and heart microvolt alternance research
- Clinical trial management and regulatory strategy
- Product development and manufacturing leadership

Brian Blaszcak

President

More than 30 years of executive-level experience working with both public and private companies.

- Business strategy and corporate development
- Capital markets and financing
- Public company compliance and governance
- Development-stage company scaling
- Preparing companies for public quoting and exchange listings
- Strategic partnerships and commercialization

SCIENTIFIC ADVISOR

Dr. Carmen Balzano, M.D.

- Former CEO of Marrilac, LLC – Hospital Acquisition & Development
- Founder and former CEO of internal medicine practice group with +100 employees
- Built, and developed over 300,000 sq. ft. of medical office space

REGULATORY ADVISOR

Jeanne Moldenhauer, M.S.

Regulatory & Quality Advisor

Senior quality and regulatory affairs executive with more than 25 years of pharmaceutical and biotechnology industry experience. Vice President of Excellent Pharma Consulting and a recognized industry educator and author.

- FDA quality and regulatory compliance
- cGMP and quality systems
- Risk management and validation
- Regulatory inspection readiness
- Industry standards development and technical publications

TECHNICAL TEAM

Led by Vladimir Podlipiski, Ph.D.

Biosignal
Processing
Engineers

AI / ML
Engineers

Software
Engineers

Quality
Systems

Product
Development

Manufacturing
Operations

OUR ADVANTAGE

Precision Heart AI combines:



SCIENTIFIC INNOVATION

Deep expertise in biosignal science, AI, and diagnostic innovation



CLINICAL EXPERIENCE

Real-world healthcare leadership and operational execution



REGULATORY EXPERTISE

Proven track record navigating FDA pathways and quality systems



CAPITAL MARKETS LEADERSHIP

Experience positioning and scaling companies for growth and liquidity



TECHNICAL EXECUTION

Building robust, scalable, and manufacturable solutions

A team purpose-built to navigate FDA clearance, commercialize ECN-DM™, and establish a new standard in preventive cardiovascular diagnostics.

SCIENCE. INNOVATION. EXECUTION. IMPACT.

MILESTONES

We have built a strong foundation.
Now we are **scaling toward impact**.



COMPLETED

We've built and validated the foundation of our technology platform.



Core technology development
Proprietary amplifier, signal processing and AI models developed.



Algorithm architecture
Advanced AI models trained on diverse biosignal datasets.



Initial validation efforts
Promising results in retrospective and prospective studies.



Regulatory planning
Engaged with regulatory experts and defined the FDA pathway.



NEXT

Executing key initiatives to bring our solution to market.



• **Clinical validation expansion**
Expand multi-center clinical studies to validate performance across diverse populations.



• **FDA submission pathway execution**
Execute regulatory strategy and submit for clearance.



• **Strategic healthcare partnerships**
Build partnerships with leading health systems and research organizations.



• **Commercial launch preparation**
Finalize go-to-market strategy, operations and commercialization readiness.



Our mission is clear: deliver **earlier insights**, **improve outcomes**, and **reduce the global burden** of cardiovascular disease.



INVESTMENT OPPORTUNITY

THE OPPORTUNITY



We are seeking **\$2M** in funding to accelerate regulatory clearance, commercialization, and market adoption.

*Precision Heart AI is building a **new diagnostic category**.*

By extracting clinically meaningful information hidden within standard ECG signals, ECN-DM seeks to enable earlier cardiovascular detection, improve patient outcomes, and reduce healthcare costs.



Seeking **strategic partners and investors** who understand the future of preventive cardiovascular medicine.



>523M

people worldwide live with cardiovascular disease.

Source: WHO, 2023



\$863B

annual cost to the U.S. healthcare system.

Source: ACC, 2023



70%

of cardiovascular disease is preventable with early detection and risk management.

Source: AHA, 2023



5.7%

CAGR of the global cardiovascular diagnostics market through 2030.

Source: Markets.us, 2023

A GROWING NEED FOR

**EARLIER.
SMARTER.
MORE ACCESSIBLE.**

CARDIOVASCULAR
DIAGNOSTICS.

OUR SOLUTION: ECN-DM™ PLATFORM



Transforms hidden ECG signals into actionable intelligence.



AI-powered analysis for earlier detection and risk stratification.



Designed to improve outcomes and reduce total cost of care.



Seamlessly integrates into existing clinical workflows.



Non-invasive, scalable, and cost-effective by design.

USE OF FUNDS



510(k)
Clearance



Manufacturing



Marketing



General
Operating
Expenses

WHY INVEST NOW

- ✓ Proprietary, defensible technology platform
- ✓ Large and growing global market
- ✓ Clear unmet need and clinical relevance
- ✓ Experienced leadership and execution plan
- ✓ Positioned to define a new diagnostic standard



Jerry Bacall

Executive Vice President

Ph: (619) 797-6988

Email: jerry@precisionheartai.com

PRECISION. SPEED. CLARITY. TRANSFORMING CARDIOVASCULAR CARE.